{"entity":{"id":"nct06998108","kind":"trial","name":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","aka":[],"tldr":"A phase 3 trial testing BEBT-209 in HR-positive / HER2-negative breast cancer, now recruiting.","summary":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy is a phase 3 interventional study registered as NCT06998108, led by BeBetter Med with Chinese Academy of Medical Sciences, and recruiting on the registry. Official title: A Multicenter, Randomised, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy. Planned enrolment is 330 participants (estimated). The study started in 2022-06-09 and primary completion is expected in 2025-12-31. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06998108","url":"https://clinicaltrials.gov/study/NCT06998108"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["bebt-209"],"companies":["bebetter-med"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06998108","phase":"3","setting":"A Multicenter, Randomized, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy","sponsor":"BeBetter Med","started":"2022-06-09","startedType":"actual","enrolled":330,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06998108/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/"}],"company":[{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/"}]}}